Okairos

At Okairos we are pioneering the development of T-cell based vaccines for major infectious diseases, including hepatitis C, malaria, respiratory syncytial virus and influenza, as well as cancer.

We are a clinical-stage company at the forefront of a new generation of potential medicines, aiming to unlock the as yet untapped significant potential of our proprietary adenovirus vectors in both prophylactic and therapeutic vaccines.

We have the strongest CD8 T-cell responses in the industry to date, a robust pipeline, an experienced management team and a knowledgeable board of directors.

04.01.12
Experimental hepatitis C vaccine shows early promise

A new vaccine against the chronic liver disease hepatitis C has shown
promising results in an early-stage clinical trial in humans. British and
Italian scientists said the experimental vaccine, which is based on a
modified cold virus and was safety-tested in 41 people, generated
immune responses similar to those seen in people who have rare but
natural defence against the disease.

13.09.11
Okairos Team Boosted by Appointment of Industry Leaders

Okairos today announced (pdf) the appointment of Bill Burns, previously Chief Executive Officer of Roche’s Pharmaceuticals Division, who becomes Chairman of the board, and Jean-Paul Prieels, former Head of Research at GSK Vaccines, who joins as a board member.
The management team has also been boosted by Tom Woiwode, new Chief Operating Officer who has served on the founding teams of four start-up biotechnology companies.

14.09.10
Announcement of a Series B Financing Round

Okairos today announced (pdf) the completion of a Series B private financing round totaling €16 million. The financing was led by Versant Ventures and joined by the Boehringer Ingelheim Venture Fund. All existing investors – BioMedPartners, LSP and Novartis Venture Funds – also participated in the round.